NASDAQ:ELVN Enliven Therapeutics (ELVN) Stock Price, News & Analysis $20.51 +0.66 (+3.32%) Closing price 05/2/2025 04:00 PM EasternExtended Trading$20.50 -0.02 (-0.07%) As of 05/2/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Enliven Therapeutics Stock (NASDAQ:ELVN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Enliven Therapeutics alerts:Sign Up Key Stats Today's Range$19.65▼$20.7950-Day Range$14.91▼$22.4652-Week Range$13.30▼$30.03Volume221,177 shsAverage Volume259,995 shsMarket Capitalization$1.01 billionP/E RatioN/ADividend YieldN/APrice Target$40.33Consensus RatingBuy Company OverviewEnliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.Read More… Enliven Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreELVN MarketRank™: Enliven Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 542nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingEnliven Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEnliven Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Enliven Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Enliven Therapeutics are expected to decrease in the coming year, from ($1.95) to ($2.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enliven Therapeutics is -10.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enliven Therapeutics is -10.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnliven Therapeutics has a P/B Ratio of 3.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Enliven Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted23.47% of the float of Enliven Therapeutics has been sold short.Short Interest Ratio / Days to CoverEnliven Therapeutics has a short interest ratio ("days to cover") of 28.1, which indicates bearish sentiment.Change versus previous monthShort interest in Enliven Therapeutics has recently increased by 2.34%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEnliven Therapeutics does not currently pay a dividend.Dividend GrowthEnliven Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted23.47% of the float of Enliven Therapeutics has been sold short.Short Interest Ratio / Days to CoverEnliven Therapeutics has a short interest ratio ("days to cover") of 28.1, which indicates bearish sentiment.Change versus previous monthShort interest in Enliven Therapeutics has recently increased by 2.34%, indicating that investor sentiment is decreasing. News and Social Media2.9 / 5News Sentiment1.25 News SentimentEnliven Therapeutics has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Enliven Therapeutics this week, compared to 3 articles on an average week. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Enliven Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,331,288.00 in company stock.Percentage Held by Insiders29.20% of the stock of Enliven Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.08% of the stock of Enliven Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Enliven Therapeutics' insider trading history. Receive ELVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enliven Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ELVN Stock News HeadlinesBenjamin Hohl Sells 3,250 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) StockMay 1 at 5:35 AM | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $80,350.00 in StockApril 24, 2025 | insidertrades.comElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.May 3, 2025 | Brownstone Research (Ad)Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CEO Sells 5,000 Shares of StockApril 22, 2025 | insidertrades.comEnliven Therapeutics, Inc. (NASDAQ:ELVN) COO Anish Patel Sells 6,667 SharesApril 10, 2025 | insidertrades.comEnliven Therapeutics: Awaiting Additional Trial DataApril 22, 2025 | seekingalpha.comEnliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual MeetingApril 2, 2025 | prnewswire.comEnliven Therapeutics, Inc.: Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business UpdateMarch 14, 2025 | finanznachrichten.deSee More Headlines ELVN Stock Analysis - Frequently Asked Questions How have ELVN shares performed this year? Enliven Therapeutics' stock was trading at $22.50 at the beginning of the year. Since then, ELVN shares have decreased by 8.8% and is now trading at $20.51. View the best growth stocks for 2025 here. How were Enliven Therapeutics' earnings last quarter? Enliven Therapeutics, Inc. (NASDAQ:ELVN) released its quarterly earnings data on Thursday, March, 13th. The company reported ($0.46) earnings per share for the quarter, topping analysts' consensus estimates of ($0.53) by $0.07. The firm earned $0.03 million during the quarter. Who are Enliven Therapeutics' major shareholders? Enliven Therapeutics' top institutional investors include Bank of New York Mellon Corp (0.19%), Rhumbline Advisers (0.11%), China Universal Asset Management Co. Ltd. (0.02%) and New York State Common Retirement Fund (0.02%). Insiders that own company stock include Joseph P Lyssikatos, Samuel Kintz, 5Am Partners Vi, Llc, Anish Patel, Rishi Gupta, Richard A Heyman, Benjamin Hohl and Rahul D Ballal. View institutional ownership trends. How do I buy shares of Enliven Therapeutics? Shares of ELVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Enliven Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Enliven Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Meta Platforms (META), Netflix (NFLX), Broadcom (AVGO), Tesla (TSLA) and Palo Alto Networks (PANW). Company Calendar Last Earnings3/13/2025Today5/03/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ELVN CIK1672619 Webimaratx.com Phone617-927-9989FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Stock Price Target$40.33 High Stock Price Target$42.00 Low Stock Price Target$39.00 Potential Upside/Downside+96.7%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.89) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-71,580,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-29.46% Return on Assets-27.33% Debt Debt-to-Equity RatioN/A Current Ratio17.44 Quick Ratio17.44 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.97 per share Price / Book3.44Miscellaneous Outstanding Shares49,004,000Free Float34,592,000Market Cap$1.01 billion OptionableOptionable Beta1.03 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:ELVN) was last updated on 5/3/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredWhat President Trump’s Executive Order 14154 means for your moneyNearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enliven Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enliven Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.